Top Rising Stocks To Invest In Right Now

Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to the downside, just as we often do when the market reacts to the upside.

Here's a look at three fallen angels trading near their 52-week lows that could be worth buying.

One lustrous investment
If you hadn't guessed by now, I'm a big fan of gold and gold miners. There are multiple factors at the moment that I feel could usher in another rally in gold prices. These include weak global economies, which make gold an attractive safe-haven investment; low domestic interest rates, which make gold attractive relative to low-yielding CDs and bonds; copious U.S. money printing, which could lead to inflation; and a contrarian mentality to buy when others are fearful. That's why I think investors would be foolish to pass up on cost-efficiency mining expert Goldcorp (NYSE: GG  ) at its current levels.

Top Rising Stocks To Invest In Right Now: Digi International Inc.(DGII)

Digi International Inc. engages in the provision of machine to machine networking products and solutions to connect, monitor, and control of local or remote physical assets by electronic means. It offers a range of embedded products, including modules, single board computers, chips, satellite communication devices, and software and development tools; and non embedded products comprising cellular products, serial servers, console servers, universal serial bus connected products, serial cards, and wireless communication adaptors. The company also provides wireless product design and development services to provide wireless networking products. In addition, it offers iDigi, a cloud-based Internet platform to connect enterprise applications to remote electronic devices. The company sells its products through a network of distributors, systems integrators, and value added resellers for a range of businesses and institutions, as well as to original equipment manufacturers primar ily in North America, Europe, the Middle East, Africa, Asia, and Latin America. It has strategic alliances with VMware, Ember, Freescale, Qualcomm, Ericsson, Itron, AT&T, Sprint, Verizon, Bell Mobility, and Rogers. The company was founded in 1985 and is headquartered in Minnetonka, Minnesota.

Advisors' Opinion:

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Digi International (Nasdaq: DGII  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Digi International doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue decreased 5.8%, and inventory increased 3.2%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue shrank 1.7%, and inventory grew 3.2%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 2.6%, and inventory grew 1.7%.

Top Rising Stocks To Invest In Right Now: TAL Education Group(XRS)

TAL Education Group, together with its subsidiaries, provides K-12 after-school tutoring services in the People?s Republic of China. It offers tutoring services to K-12 students covering various academic subjects, including mathematics, English, Chinese, physics, chemistry, and biology. The company provides tutoring services through small classes; personalized premium services, such as one-on-one tutoring; and online course offerings. As of May 31, 2011, it operated a network of 199 physical learning centers in Beijing, Shanghai, Guangzhou, Shenzhen, Tianjin, Wuhan, Nanjing, Hangzhou, Chengdu, and Xi?an; and eduu.com, an online education platform for online courses. The company also offers education and management consulting services, as well as sells software. It operates under the Xueersi brand. The company was founded in 2003 and is headquartered in Beijing, China.

Advisors' Opinion:

• [By Louis Navellier]

  Education is a top priority in China and competition for the best schools are intense. TAL� Education Group (XRS) benefits form the focus on education by offering tutoring services for kids in grades k-12. They operate a network of 270 learning centers and 247 service centers in China and also have 5 call centers in Beijing, Shanghai, Tianjin, Guangzhou, and Shenzhen.

• [By Lisa Levin]

  TAL Education Group (NYSE: XRS) shares rose 4.30% to $20.86. The volume of TAL Education Group shares traded was 318% higher than normal. TAL Education's PEG ratio is 1.14.

Top High Dividend Stocks To Own Right Now: Tellabs Inc.(TLAB)

Tellabs, Inc. designs, develops, and supports telecommunications networking products for communication service providers in the United States and internationally. Its products and services enable customers to deliver wireless and wireline voice, data, and video services to business and residential customers. The company operates through three segments: Broadband, Transport, and Services. The Broadband segment provides access products that enable service providers to deliver bundled voice, video, and high-speed Internet/data services over copper or fiber networks; managed access products, which deliver wireless and business services primarily outside of North America; and data products, including packet-switched products that enable wireless and wireline carriers to deliver mobile voice and Internet services, and wireline business services to their customers. The Transport segment enables service providers to manage network bandwidth by adding capacity needed; and wireline and wireless providers to support metro networks, mobile services, and business services for enterprises, as well as triple-play voice, video, and data services for residential consumers. The Services segment delivers deployment, training, support, and professional services, which support various phases of the network, such as planning, building, and operating. Tellabs, Inc. serves primarily communication services providers, including local exchange carriers; wireline and wireless service providers; multiple system operators; competitive service providers; distributors; original equipment manufacturers; system integrators; and government agencies. The company sells its products and services through its direct sales and sales support personnel, value-added resellers, independent sales representatives, distributors, and public and private network providers. Tellabs, Inc. was founded in 1974 and is headquartered in Naperville, Illinois.

Advisors' Opinion:

• [By SA Pro Top Ideas]

  Stock Movers and Great Calls
  Alpha-Rich long and short ideas regularly move stocks and identify stocks that are about to move. Some notable recent calls subscribers had early access to:

  Saidal Mohmand argued Wednesday that Tellabs (TLAB) was a strong assets play on the verge of a turnaround. The stock is +5.9% since. Read article » On June 13, Stephen Lin said that Ellie Mae's (ELLI) dominant position could mean 45% upside. Shares are +30.7% since. Read article »

  To Come Today
  Don't forget to check your SA Pro dashboard later today for the latest Alpha-Rich ideas, including a REIT with strong management and many catalysts. Any thoughts to share on the latest Alpha-Rich ideas? Leave a comment here. Have a great weekend.
  
  SA Pro Editors
  …............
  
  The SA Pro team is Eli Hoffmann (Editor in Chief), Rachael Granby (Editorial Product Manager), Daniel Shvartsman, Samir Patel, Michael McDonald, and Jeffrey Fischer (Senior Pro Editors). You can reach us at pro-editors@seekingalpha.com.

• [By Rich Smith]

  You have to hand it to Tellabs (NASDAQ: TLAB  ) -- they work fast.

  Late last month, the networking equipment maker had to scramble when its acting chief financial officer, Tom Minichiello, announced plans to retire on July 12 to become the new CFO at Westell Technologies (NASDAQ: WSTL  ) . On Friday, though, just as the deadline was happening, Tellabs announced that it has found a replacement.

• [By Selena Maranjian]

  The biggest new holdings are Seagate Technology�and Warner Chilcott. Other new holdings of interest include Tellabs (NASDAQ: TLAB  ) and Windstream (NASDAQ: WIN  ) . Tellabs offers a satisfying dividend yield of 3.7%, but the networking equipment maker has been facing some headwinds, such as the death of its CEO and the recent departure of its CFO. Its performance has been spotty, besting estimates in its fourth quarter but disappointing them in the recent first quarter.

• [By Rick Munarriz]

  Thursday
  Tellabs (NASDAQ: TLAB  ) checks in on Thursday. The provider of mobile backhaul, packet optical, and services solutions to communications services lost its CEO to colon cancer last year. It has also lost its mojo. Wall Street sees Tellabs merely breaking even in 2013 on a 14% decline in revenue.

Top Rising Stocks To Invest In Right Now: Euro/Swiss(RF)

Regions Financial Corporation operates as the holding company for Regions Bank that provides a range of commercial, retail, and mortgage banking services in the United States. It offers various deposit products, including savings and transaction accounts; demand deposit accounts; money market accounts; and time deposits, such as certificate of deposits and individual retirement accounts. The company?s loan portfolio comprises commercial loans, such as commercial and industrial, and owner occupied commercial real estate mortgage and construction loans; investor real estate loans, including commercial real estate mortgage and construction loans; and consumer loans, which consist of residential first mortgage, home equity, indirect, consumer credit card, and other consumer loans. Regions Financial Corporation, through other subsidiaries, also provides regional brokerage and investment banking products and services, such as securities brokerage, trust, asset management, finan cial planning, mutual funds, securities underwriting, sales and trading, and investment banking services for individual and institutional investors; and insurance brokerage services for various lines of personal and commercial insurance comprising property, casualty, life, health, and accident. In addition, the company offers credit-related insurance, including title, term life, credit life, environmental, crop, and mortgage insurance; debt cancellation products; and equipment financing products primary for commercial clients. As of December 31, 2011, it operated approximately 2,100 ATMs and 1,726 banking offices in Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Texas, and Virginia. The company was founded in 1970 and is headquartered in Birmingham, Alabama.

Advisors' Opinion:

• [By Amanda Alix]

  Banks are anxious to make money off of their mobile customers, but they don't relish�the type of backlash B of A experienced. Yet, banks have a point. Downloadable apps cost money to create, with estimates of between $1 million and $5 million for each project.�Surely, banks can be excused for wanting to recoup some of that investment in research and development. Some already do --�U.S. Bancorp (NYSE: USB  ) has been charging $0.50 per mobile check deposit for over two years, and Regions Financial (NYSE: RF  ) charges for this service, too. U.S. Bancorp notes that customers have willingly paid for this amenity, and Regions plans to further monetize its mobile banking services platform.

• [By Eric Volkman]

  Following last month's bank stress tests from the Federal Reserve, Regions Financial (NYSE: RF  ) is fulfilling its stated aim to increase its dividend. The lender will pay its stockholders a quarterly distribution of $0.03 per share, to be dispensed on July 1 to shareholders of record as of June 14. Previously, the company had handed out $0.01 per share in every quarter dating back to Sept 2009.

• [By Matthew Smith]

  We also think that Regions Financial (RF) should be bought on the weakness in their share price right now. The shares trade roughly $1/share below their 52-week high right now but with what we see happening in the financial space over the next few months and few years we think that this name is a deal under $10/share. Like the discount brokers, as the yield curve steepens the company's profits shall increase and with that taking place and the continued improvement in the company's balance sheet we think share buybacks and dividends will be carried out and even raised.

• [By Robert Eberhard]

  Regions Financial (NYSE: RF  ) will release its first-quarter earnings tomorrow morning, and investors are facing a big question: Will CEO Grayson Hall and crew deliver good news? Or should investors be fretting the upcoming release?

Top Rising Stocks To Invest In Right Now: Hyperion Therapeutics Inc (HPTX)

Hyperion Therapeutics, Inc. (Hyperion), incorporated in November 2006, is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company develops Ravicti (glycerol phenylbutyrate) to treat the prevalent urea cycle disorders (UCD) and hepatic encephalopathy (HE). The Company has completed two Phase II trials and one pivotal Phase III trial of Ravicti. The Company�� HE clinical program consists of two trials, which have enrolled patients with cirrhosis. On December 23, 2011, the Company submitted a new drug application (NDA) for Ravicti for the chronic management of UCD in patients aged six years and above based on data from its pivotal Phase III trial in adult patients and the results of two Phase II trials, one in adults and one in pediatric patients aged 6 through 17 years. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.

In June 2011, the Company completed a 24-month carcinogenicity study of Ravicti in rats. On March 22, 2012, pursuant to an asset purchase agreement (purchase agreement) with Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation, the Company purchased all of the worldwide rights to Ravicti. The Company also has an option to acquire all of Ucyclyd�� worldwide rights in BUPHENYL and AMMONUL (sodium phenylacetate and sodium benzoate) injection.

The Company conducted a pivotal Phase III trial of Ravicti in adult patients 18 years of age or older with UCD. The Company completed a second Phase II trial at five centers in North America in UCD patients aged 6 through 17 years. This trial includes two phases: a two-week, open-label, safety, tolerability, pharmacokinetic characteristics and ammonia control of Ravicti. The Co! mpany enrolled 77 adult and pediatric UCD patients in its two 12-month open-label safety studies, 69 of whom completed the studies. The Company conducted nonclinical genotoxicity and carcinogenicity studies to assess the tumorigenic potential of Ravicti in animals and to assess the relevant risk in humans. The Company is conducting a Phase II multi-center study of patients with cirrhosis and episodic HE.

Advisors' Opinion:

• [By Jesse Solomon]

  NPS Pharmaceuticals (NPSP), for example, created a drug for treating short bowel syndrome. And Hyperion Therapeutics (HPTX) is developing a drug for hepatic encephalopathy, a decline of brain function that according to the National Institute of Health occurs when the liver is no longer able to remove toxins from the blood. Those stocks are up 20% and 40%, respectively, this year.

• [By Sean Williams]

  What: Shares of Hyperion Therapeutics (NASDAQ: HPTX  ) , a biopharmaceutical company focused on treatments for orphan diseases and hepatology, rose as much as 10% after receiving orphan drug exclusivity status for Ravicti from the Food and Drug Administration, and exercising an option to acquire two additional urea cycle drugs from Valeant Pharmaceuticals (NYSE: VRX  ) .

Top Rising Stocks To Invest In Right Now: Shire PLC (SHPG)

Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.

VANSE/ VENVANSE

VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.

ADDERALL XR

ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.

INTUNIV

INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.

EQUASYM

Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.

LIALDA/MEZAVANT

LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.

PENTASA

PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.

RESOLOR

RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.

XAGRID

XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.

REPLAGAL

REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.

ELAPRASE

ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.

VPRIV

VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.

FIRAZYR

FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.

DERMAGRAFT

DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.

The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.

Advisors' Opinion:

• [By Alexander Maxwell]

  The market for the treatment of chronic diabetic foot ulcers has been growing and larger companies have been taking notice. Many large pharmaceutical companies have their own treatments for chronic diabetic foot ulcers. The space has also caused some major acquisitions. In 2011, Shire� (NASDAQ: SHPG  ) acquired�a drug called Dermagraft for the treatment of slow-healing diabetic foot ulcers, through its $750 million acquisition of�Advanced BioHealing. Dermagraft has been a rather lucrative product for Shire, with $153.8 million in sales�last year. As the market continues to grow, I would look for more partnerships with large pharmaceutical companies, and of course more research and development dollars being devoted toward the chronic diabetic foot ulcers indication.

Top Rising Stocks To Invest In Right Now: Rio Tinto Plc(RIO)

Rio Tinto plc engages in finding, mining, and processing mineral resources. The company produces aluminum products, including bauxite, alumina, and aluminum; copper, gold, molybdenum, silver, and nickel; diamonds; minerals, such as borates, titanium dioxide feedstocks, high purity iron, metal powders, zircon, and rutile; thermal and coking coal, and uranium; and iron ore and salt. It primarily operates in Australia, North America, South America, Asia, Europe, and southern Africa. The company was founded in 1873 and is headquartered in London, the United Kingdom. Rio Tinto plc is a subsidiary of Rio Tinto Group.

Advisors' Opinion:

• [By Ben Levisohn]

  Shares of Cliffs Natural Resources have dropped 2% to $13.86 at 10:17 a.m. today–and yes, the damage is specific to Cliffs.�Rio Tinto�(RIO) has dipped 0.1% $51.56 despite getting downgraded today, while BHP Billiton (BHP) has gained 0.9% to $67.37.

• [By Ben Levisohn]

  It’s been a bad day for iron miners like iron miners like BHP Billiton (BHP), Rio Tinto (RIO) and Vale (VALE) after Morgan Stanley cut its iron-ore price estimates. For Cliffs Natural Resources (CLF), the damage could be even worse.

• [By Ben Levisohn]

  Shares of Cliffs Natural Resources have fallen 2.7% to $18.59 at today at 3:42 p.m., while Rio Tinto (RIO) has fallen 3.6% to $53.36, BHP Billiton (BHP) has dropped 2.2% to $66.64 and Vale (VALE) has plunged 5% to $13.05.

• [By Brian Pacampara]

  So what: Unfortunately for Turquoise, and parent company Rio Tinto (NYSE: RIO  ) , the Mongolian parliament is currently in summer recess and the approval process will take plenty of time even after that, so all work on the underground development will be put on hold indefinitely. Given that Oyu Tolgoi is Turquoise's primary operation -- total capital invested in the mine to March 31 was about $6 billion -- the delay represents a huge setback for management and raises plenty of uncertainty for shareholders. �

Top Rising Stocks To Invest In Right Now: AECOM Technology Corp (ACM)

AECOM Technology Corporation (AECOM) is a provider of professional technical and management support services for commercial and government clients around the world. The Company provides planning, consulting, architectural and engineering design, and program and construction management services for a range of projects, including highways, airports, bridges, mass transit systems, government and commercial buildings, water and wastewater facilities, and power transmission and distribution. It also provides program and facilities management and maintenance, training, logistics and other support services, for agencies of the United States government. It offers services in two segments: Professional Technical Services and Management Support Services. In June 2011, the Company acquired Spectral Services Consultants Pte. Ltd.

Professional Technical Services (PTS)

The PTS segment delivers planning, consulting, architectural and engineering design, and program and construction management services to commercial and government clients worldwide in end markets, such as transportation, facilities, environmental, energy, water and government markets. It provides program management services through a joint venture for the Second Avenue subway line in New York City, design and contract administration services for the Hong Kong-Zhuhai-Macao Bridge's Hong Kong Boundary Crossing Facilities and engineering and environmental management services to support global energy infrastructure development for a number of petroleum and mining companies.

PTS segment contributed 86% of the Company�� revenue during the fiscal year ended September 30, 2011 (fiscal 2011).

Transit and rail projects include light rail, heavy rail (including high speed, commuter and freight) and multimodal transit projects. The Company provided engineering design services for the new World Trade Center Terminal for PATH and the Second Avenue Subway (8.5-mile rail route and 16 stations) in New York City, the Ma O! n Shan Rail (seven-mile elevated railway) in Hong Kong, and Crossrail (74-mile railway) in the United Kingdom. Marine, Ports and Harbors Projects include wharf facilities and container port facilities for private and public port operators. The Company provided marine design and engineering services for container facilities in Hong Kong, the Ports of Los Angeles, Long Beach, New York and New Jersey. Highways, Bridges and Tunnels Projects include interstate, primary and secondary urban and rural highway systems and bridge projects. Aviation Projects include landside terminal and airside facilities and runways as well as taxiways.

Government Projects include the Company�� emergency response services for the Department of Homeland Security, including the Federal Emergency Management Agency and engineering and program management services for agencies of the Department of Defense. It also provides architectural and engineering services for national laboratories, including the laboratories at Hanford, Washington and Los Alamos, New Mexico. Industrial Projects include industrial facilities for a variety of end markets, including manufacturing, distribution, aviation, aerospace, communications, media, pharmaceuticals, renewable energy, chemical, and food and beverage facilities. Urban Master Planning/Design Projects include design services, landscape architecture, general policy consulting and environmental planning projects for a variety of government, institutional and private sector clients. It provides strategic planning and master planning services for new cities and mixed use developments in the People�� republic of China, Southeast Asia, the Middle East, North Africa, the United Kingdom and the United States.

Commercial and Leisure Facilities Projects include corporate headquarters, high-rise office towers, historic buildings, hotels, leisure, sports and entertainment facilities, hospitals and healthcare facilities and corporate campuses. Institutional Projects include engin! eering se! rvices for college and university campuses, including the new Kennedy-King College in Chicago, Illinois. It has also undertaken assignments for Oxford University in the United Kingdom, Pomona College and Loyola Marymount University in California. Healthcare Projects include design services for the Mayo Clinic Gonda Building in Rochester, Minnesota, University Hospital in Dubai Healthcare City and the Samsung Cancer Center in Seoul, Korea. It has also undertaken assignments for the new Veterans Affairs Medical Center in Orlando, Florida, and the Minneapolis campus of Children's Hospitals and Clinics of Minnesota. Correctional Projects include the planning, design, and construction of detention and correction facilities throughout the world.

Water and Wastewater Projects include treatment facilities as well as supply, distribution and collection systems, stormwater management, desalinization, and other water re-use technologies for metropolitan governments. Environmental Management Projects include remediation, waste handling, testing and monitoring of environmental conditions and environmental construction management for private sector clients. Water Resources Projects include regional-scale floodplain mapping and analysis for public agencies, along with the analysis and development of protected groundwater resources for companies in the bottled water industry.

Demand Side Management Projects include energy efficient systems for public K-12 schools and universities, health care facilities, and courthouses and other public buildings, as well as energy conservation systems for utilities. Transmission and Distribution Projects include power stations and electric transmissions and distribution and co-generation systems, including enhanced electrical power generation in Stung Treng, Cambodia. These projects utilize a range of services that include consulting, forecasting and surveying to detailed engineering design and construction management. Alternative/Renewable Energy Projects ! include p! roduction facilities, such as ethanol plants, wind farms and micro hydropower and geothermal subsections of regional power grids. It provides site selection and permitting, engineering, procurement and construction management and related services. Hydropower/Dams Projects include hydroelectric power stations, dams, spillways, and flood control systems including the Song Ba Ha Hydropower Project in Vietnam, the Pine Brook Dam in Boulder County, Colorado and the Peribonka Hydroelectric Power Plant in Quebec, Canada. Solar Projects include performing environmental work for the solar photovoltaic Brockton Brightfield project in New England, and environmental permitting services for the California Energy Commission to permit the development of a 250 mega watts (MW) solar thermal power plant in the Mojave Desert of California.

Management Support Services (MSS).

The MSS segment provides program and facilities management and maintenance, training, logistics, consulting, technical assistance and systems integration services, for agencies of the United States government. It also provides organizational and limited direct support services for equipment sent to the United States Army's Corpus Christi Depot in Texas. The MSS segment contributed 14% of the Company�� fiscal 2011 revenue.

Installation, Operations and Maintenance Projects include Department of Defense and Department of Energy installations where the Company provides services for the operation and maintenance of complex government installations, including military bases, test ranges and equipment. It also provides services for the operations and maintenance of the Department of Energy's Nevada Test Site. Logistics and Field Services Projects include logistics support services for a number of Department of Defense agencies and defense contractors focused on developing and managing integrated supply and distribution networks. Training Projects include training applications in live, virtual and simulation training! environm! ents. Systems Support Projects cover a set of operational and support systems for the maintenance, operation and modernization of Department of Defense and Department of Energy installations. Its services in this area range from information technology and communications to life cycle optimization and engineering, including environmental management services.

Technical Personnel Placement Projects include the placement of personnel in functional areas of military and other government agencies, as these entities continue to outsource critical services to commercial entities. It provides systems, processes and personnel in support of the Department of Justice's management of forfeited assets recovered by law enforcement agencies. It also supports the Department of State in its enforcement programs by recruiting, training and supporting police officers for international and homeland security missions. Field Services Projects include maintaining, modifying and overhauling ground vehicles, armored carriers and associated support equipment both within and outside of the United States under contracts with the Department of Defense. It also maintains and repairs telecommunications systems for military and civilian entities.

Advisors' Opinion:

• [By Rich Smith]

  Continuing to laze its way through summer, the U.S. Department of Defense announced only nine mostly small new contracts Tuesday, totaling just a bit over $87 million in aggregate value. Winners today included:

Top Rising Stocks To Invest In Right Now: Philip Morris International Inc(PM)

Philip Morris International Inc., through its subsidiaries, engages in the manufacture and sale of cigarettes and other tobacco products in markets outside of the United States. Its international product brand line comprises Marlboro, Merit, Parliament, Virginia Slims, L&M, Chesterfield, Bond Street, Lark, Muratti, Next, Philip Morris, and Red & White. The company also offers its products under the A Mild, Dji Sam Soe, and A Hijau in Indonesia; Diana in Italy; Optima and Apollo-Soyuz in the Russian Federation; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics, and Number 7 in Canada; Best and Classic in Serbia; f6 in Germany; Delicados in Mexico; Assos in Greece; and Petra in the Czech Republic and Slovakia. It operates primarily in the European Union, Eastern Europe, the Middle East, Africa, Asia, Canada, and Latin America. The company is based in New York, New York.

Advisors' Opinion:

• [By Lawrence Meyers]

  That means you should go with either Altria Group (MO) or Philip Morris International (PM). And if you’re only interested in buying one, I think I�� select MO stock. It pays a slightly better divided (5.2% vs. 4.7%).

• [By Selena Maranjian]

  Other large-cap stocks didn't do quite so well over the last year but could see their fortunes change in years to come. Philip Morris International (NYSE: PM  ) , for example, gained 5% and yields 4.1%. With domestic tobacco companies challenged by tightening regulations, rising taxes, and a shrinking smoking base, many have assumed that Philip Morris is the best bet in tobacco. But in the third quarter, it posted the weakest results, with volume taking a sizable drop and a strong dollar reducing its earnings. Bulls like its innovation and share buybacks.

• [By Efficient Alpha]

  Philip Morris International (PM) is a favorite of mine, not only for its 4% dividend but also for its protection against global inflationary pressures. The company can pass through higher commodity prices and smokers will keep coming back for more. The company has 16% of the international market and is making strong progress in China. Asia accounts for 36% of sales, followed by the EMEA region (27%), the EU (26%) and Latin America/Canada (11%). Shares have posted an annual return of 15% since its spinoff in 2008.

• [By Ben Levisohn]

  Shares of Phillip Morris (PM) have been performing about as well as a soggy cigarette–but Morgan Stanley still hopes they will catch fire.

  Agence France-Presse/Getty Images

  How bad has performance of Phillip Morris been? Its shares have dropped 1.9% during the past 12 months, while American-focused Altria Group (MO) has gained 15%. British American Tobacco (BTI) has gained 3%, Reynolds American (RAI) has advanced 14%, and Lorillard (LO) has jumped 26%.

  And now Morgan Stanley’s David Adelman and team have cut their earnings-per-share forecast for Phillip Morris by 11 cents thanks to the strong dollar, after cutting it by 41 cents six weeks ago. Adelman explains why:

  While PM�� significant EM exposure has been an important driver of its 8%+ constant-currency 2008-2013 EBIT CAGR, recent weakness in a number of important EM currencies (e.g., Argentina, Turkey and Indonesia) will undoubtedly weigh on 2014 reported results. Further, it remains somewhat unclear the extent to which added Yen weakness will impact results, as PM�� F/X guidance already suggests that it was somewhat hedged on USD/Yen. Finally, with ~60% of its operating expenses denominated in ��ard dollar��currencies (USD, EUR and CHF), we have also incorporated a significant estimated transactional F/X impact (+40% of our $0.52/share est.).

  Still, Adelman kept Phillip Morris rated Overweight. He explains why:

  Remain OW, as stock should benefit from recent weakness and achievable 2014 targets: After underperforming US Tobacco and Staples by 18% and 24%, respectively, in 2013, and with expectations already lowered to a conservative level of 6-8% currency-neutral underlying EPS growth in 2014, we believe current valuation of ~14.5x 2015e P/E and <10x EV/EBITDA remains attractive. We continue to view local-currency earnings risk as to the upside, particularly as no new issues have appeared to emerge entering 2014 (such as unforeseen outsized excise

Top Rising Stocks To Invest In Right Now: Axcelis Technologies Inc.(ACLS)

Axcelis Technologies, Inc., together with its subsidiaries, designs, manufactures, and services ion implantation, dry strip, and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. It offers a line of high energy, high current, and medium current ion implanters for various applications, such as line of single wafer implanters, known as the Optima platform, comprising the Optima XE, the Optima HD, and the Optima MD. The company also offers dry strip tools, including the Integra RS, which comprises paired-chamber process modules. In addition, it provides aftermarket services and support, such as spare parts, equipment upgrades, maintenance services, and customer training. The company sells its equipment and services through direct sales force, distributors, and manufacturing representatives. Axcelis Technologies was founded in 1995 and is headquartered in Beverly, Massachusetts.

Advisors' Opinion:

• [By Stephen Simpson, CFA]

  The major dry strip product today is Suprema - Mattson's most advanced tool, and one that uses inductively coupled plasma (ICP) technology and vacuum transfer. Two of the company's primary competitors use one but not the other, while the third uses both but charges about 20% more for its tools. According to Gartner, Mattson holds about 22% market share in this roughly $180 million/year market, with Lam Research (which acquired Novellus and dry strip IP from Axcelis (ACLS)) and PSK as the primary competitors.

• [By Ben Axler]

  An old spin-out of Eaton Corp. (ETN), Axcelis Technologies (ACLS) designs, manufactures and services ion implantation, dry strip and other processing equipment used in the fabrication of semiconductor chips. The semiconductor capital equipment industry is very cyclical, and as a smaller player in the industry, ACLS has not been immune, and gone through protracted periods of losses. In the past few years, the company has taken numerous steps to reposition itself for the next cyclical upswing by listening to its customers and investing heavily in R&D to revamp its product line to expand its addressable market opportunity, right-sizing its cost structure to substantially lower its breakeven level, establishing new collaborative partnerships, and optimizing its balance sheet to unlock value. Now with signs of a cyclical upswing occurring, and being led by memory - Micron (MU) and SanDisk (SNDK), ACLS is poised for accelerating earnings potential beginning in Q4'2013 that could drive its stock price substantially higher. However, with a few nearer-term catalysts on the horizon, investors may not want to wait too long before purchasing shares. As an early indicator, investors should consider that insiders recently purchased the stock in the open market in August at current levels. These stock purchases coincide with the one year anniversary of ACLS's new Purion M product line entering an evaluation period with a major customer. Sell-side analysts are starting to take notice and listening in to the company's recent conference call, which at least opens the door to new broker initiations in the future. The downside risk appears mitigated by ACLS's strengthened balance sheet, and dramatically improved operating financial model that has stemmed further cash burn. As the company hits an inflection point with new customer contracts and proves its earnings cycle is under way, we expect ACLS's valuation discount to peers to narrow and the stock to appreciate substantially